TuHURA Biosciences (HURA) Long-Term Debt Issuances (2020 - 2025)
TuHURA Biosciences' (HURA) quarterly Long-Term Debt Issuances came in at $2.9 million in Q4 2025, down 89.84% quarter-over-quarter from $28.6 million in Q3 2024.
TuHURA Biosciences (HURA) Long-Term Debt Issuances (2020 - 2025) Analysis & Trends
TuHURA Biosciences' Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at $2.9 million for Q4 2025.
- On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $2.9 million in Q4 2025; TTM through Dec 2025 was $55.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.0 million, down 89.5% from the prior year.
- Long-Term Debt Issuances slipped to $2.9 million in Q4 2025 per HURA's latest filing, from $28.6 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $28.6 million in Q3 2024 and bottomed at $2.9 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | TuHURA Biosciences | 132.62 Mn | 132.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.90 Mn |
| Dec 31, 2025 | 2.90 Mn |
| Sep 30, 2024 | 28.57 Mn |
| Sep 30, 2024 | 28.57 Mn |
| Jun 30, 2024 | 19.07 Mn |
| Jun 30, 2024 | 19.07 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Sep 30, 2020 | 500,000.00 |
| Sep 30, 2020 | 500,000.00 |